Founded in 2012, Avidity is developing a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates to treat genetic neuromuscular diseases.
Our summer crowdfunding campaign has begun! Every dollar powers reliable news in your neighobrhood.
Founded in 2012, Avidity is developing a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates to treat genetic neuromuscular diseases.
Will you chip in? We need to raise $10,000 by June 30 to bring more trustworthy journalism to communities across San Diego.